Autoplaque vs Imbio PHA (4.0.0)
AI Verdict
Choose Autoplaque if…
Choose Autoplaque if your primary objective is a comprehensive, quantitative analysis of coronary artery plaque burden and luminal stenosis from CT angiography images. This tool is ideal for detailed cardiovascular risk stratification and guiding long-term treatment strategies for patients with suspected or known coronary artery disease.
View Autoplaque →Choose Imbio PHA (4.0.0) if…
Choose Imbio PHA (4.0.0) if you require rapid, automated measurements of cardiac structures from CT pulmonary angiogram (CTPA) scans to assess potential right ventricular dilation. This software is best suited for aiding in the diagnosis and risk stratification of acute conditions like pulmonary embolism or monitoring chronic conditions such as pulmonary hypertension.
View Imbio PHA (4.0.0) →Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Quick Comparison
| Feature | Autoplaque | Imbio PHA (4.0.0) |
|---|---|---|
| Deployment | Workstation-based post-processing application, runs on Windows or Mac OS. | Cloud (AWS) or On-premise (VMware) or via partners (Nuance, Aidoc, Siemens Syngo.via, TeraRecon, FerrumHealth, Flywheel). |
| FDA Status | Cleared AI-estimated | Yes AI-estimated |
Head-to-Head
AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.
Usability
Imbio PHA (4.0.0)Imbio PHA emphasizes a fully automated, rapid assessment that integrates seamlessly into existing DICOM workflows, requiring no new user interfaces for clinicians. This approach prioritizes efficiency and minimal disruption to clinical practice. Autoplaque, while offering interactive review and editing, is workstation-based, which may present a higher barrier to integration into diverse enterprise environments.
Clinical Value
TieBoth tools offer significant clinical value by providing FDA-cleared, AI-powered quantitative analysis for critical cardiovascular conditions. Autoplaque aids in heart attack risk prediction through detailed coronary plaque analysis, while Imbio PHA assists in the diagnosis and risk stratification of pulmonary embolism and hypertension by assessing right ventricular dilation. Their distinct applications address equally important clinical needs with validated results.
Pricing & Value
TieNeither Autoplaque nor Imbio PHA disclose their pricing information in the provided structured facts or publicly available web searches. Without any transparent pricing details, it is impossible to conduct a head-to-head comparison of their cost-effectiveness or overall value proposition.
Enterprise Readiness
Imbio PHA (4.0.0)Imbio PHA demonstrates superior enterprise readiness with explicit HIPAA compliance (third-party certified) and flexible deployment options including cloud, on-premise, and through various partners. Autoplaque, as workstation-based software with no specified HIPAA compliance or BAA, appears less equipped for broad enterprise adoption and integration into complex healthcare IT infrastructures.
Innovation
AutoplaqueBoth tools leverage AI for advanced image analysis, but Autoplaque's focus on detailed quantitative analysis of atherosclerotic plaque morphology, including automated segmentation and the ability to aid in heart attack risk prediction up to five years in advance, showcases a slightly higher degree of specialized innovation in preventative cardiology. Its provision of age- and sex-specific plaque volume thresholds further enhances its innovative approach to personalized risk assessment.
Support & Docs
Imbio PHA (4.0.0)Imbio PHA clearly outlines its customer support infrastructure, offering 24/7/365 support via phone and email, along with an online case submission system and readily available user manuals. In contrast, Autoplaque, developed by a medical center and licensed to a startup, has less publicly detailed information regarding dedicated customer support channels and documentation availability.
Feature-by-Feature
Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.
| Feature | Autoplaque | Imbio PHA (4.0.0) |
|---|---|---|
| Company | Cedars-Sinai Medical Center: AIM | Imbio |
| Description | Autoplaque, developed by Cedars-Sinai AIM, is an FDA-cleared AI-powered software for quantitative analysis of coronary plaques and luminal stenoses from CT angiography images, aiding in heart attack risk prediction and treatment guidance. | Imbio PHA (4.0.0) is an FDA-cleared AI-powered medical image processing software that automatically measures cardiac structures from CT pulmonary angiogram (CTPA) scans to assess potential right ventricular dilation and aid in the diagnosis and risk stratification of pulmonary embolism and hypertension. |
| Categories | Cardiology AI, Radiology & Imaging AI | Cardiology AI, Radiology & Imaging AI |
| Specialties | Cardiology, Radiology | Cardiology, Pulmonology, Radiology |
| Key Features | AI-powered quantitative analysis of atherosclerotic plaque; Detection and characterization of coronary artery plaque; Measurement of luminal stenoses; Analysis of coronary anatomy and pathology from CT Angiographic images; Workstation-based post-processing application; Automated vessel, plaque, and lumen segmentation (reviewable and editable by clinician); Review of heart and coronary vessels in Multiplanar Reformatting (MPR), curved MPR, and straightened MPR views; Measurement of vessel diameter and area | Automated measurement of right and left ventricle diameters; Automated measurement of main pulmonary artery and aorta diameters; Calculates RV/LV and PA/Ao ratios; Utilizes artificial intelligence algorithms for anatomical identification and measurement; Generates annotated DICOM images; Provides summary reports in PDF format; Integrates with native DICOM tools and workflows; Rapid, fully-automated assessment (typically in minutes) |
Videos
Demos, reviews, and walkthroughs featuring Autoplaque and Imbio PHA (4.0.0).